OVID — Ovid Therapeutics Share News
0.000.00%
Last trade - 00:00- $462.86m
- $345.64m
- $7.25m
Brief: Ovid Therapeutics- On May 10, Takeda Notified Co Takeda Planned To Announce Two Pivotal Phase 3 Programs Evaluating Soticlestat Are Likely To Be Delayed
Ovid Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ovid Therapeutics Reports First Quarter 2022 Financial Results
Ovid Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Ovid Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ovid Therapeutics Reports Business Update, Fourth Quarter And Full Year 2021 Financial Results
Ovid Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Healx And Ovid Therapeutics To Enter Strategic Partnership
Ovid rises on license deal with AstraZeneca for epilepsy therapies
Brief: Ovid Therapeutics Expands Epilepsy Franchise With Novel KCC2 Activators
Ovid Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Ovid Therapeutics Reports Q3 Loss Per Share Of $0.17
Brief: Ovid Therapeutics Reports Q3 Loss Per Share $0.28
Ovid Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Ovid Therapeutics Reports Second Quarter 2021 Financial Results
Ovid Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Ovid Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Ovid Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Ovid Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview